Last reviewed · How we verify
NTRX-07
At a glance
| Generic name | NTRX-07 |
|---|---|
| Also known as | MDA7 |
| Sponsor | NeuroTherapia, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of NTRX-07 in Participants With Alzheimer's Disease (PHASE2)
- A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 (PHASE1)
- Safety and Tolerability of NTRX-07 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTRX-07 CI brief — competitive landscape report
- NTRX-07 updates RSS · CI watch RSS
- NeuroTherapia, Inc. portfolio CI